The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the treatment of generalized myasthenia gravis.

And there's a number of resources now online from the government, as well as from the National Infusion Center, as well as Lilly has a phone number, and Regeneron, who also makes antibodies ...

Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

UPMC gives monoclonal antibody infusions at 16 fixed locations, as well as in some Emergency Departments, long-term care facilities and at patient's homes. Disclaimer: AAAS and EurekAlert!

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

61% developed antibodies. A concentration of 8.0 µg/ml or greater was associated with a shorter duration of clinical response and a 2.40 increased risk of infusion reactions. [91] However ...

Nivolumab is a monoclonal antibody that works by binding to a protein called PD-1 on a type of immune cell called T-cell.

Immune globulin (human) 10% (100mg/mL); liq for IV or SC infusion; preservative-, sucrose- and latex-free. Gammagard Liquid supplies a broad spectrum of opsonizing and neutralizing IgG antibodies ...

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...